Free Trial

Cellectis (CLLS) Competitors

Cellectis logo
$1.62 +0.02 (+0.93%)
Closing price 03:56 PM Eastern
Extended Trading
$1.60 -0.02 (-1.23%)
As of 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CLLS vs. AMRN, AQST, PRTA, TERN, PRME, HUMA, SNDL, HRTX, AURA, and ALT

Should you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include Amarin (AMRN), Aquestive Therapeutics (AQST), Prothena (PRTA), Terns Pharmaceuticals (TERN), Prime Medicine (PRME), Humacyte (HUMA), SNDL (SNDL), Heron Therapeutics (HRTX), Aura Biosciences (AURA), and Altimmune (ALT). These companies are all part of the "pharmaceutical products" industry.

Cellectis vs. Its Competitors

Cellectis (NASDAQ:CLLS) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Cellectis presently has a consensus target price of $4.00, indicating a potential upside of 146.15%. Amarin has a consensus target price of $12.00, indicating a potential downside of 30.76%. Given Cellectis' stronger consensus rating and higher probable upside, analysts clearly believe Cellectis is more favorable than Amarin.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellectis
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Amarin
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Cellectis has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellectis$47.63M1.90-$36.76M-$0.86-1.89
Amarin$228.61M1.57-$82.18M-$3.64-4.76

In the previous week, Cellectis and Cellectis both had 1 articles in the media. Cellectis' average media sentiment score of 0.37 beat Amarin's score of -0.13 indicating that Cellectis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cellectis
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Amarin
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

63.9% of Cellectis shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 16.4% of Cellectis shares are held by insiders. Comparatively, 2.0% of Amarin shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Amarin has a net margin of -41.07% compared to Cellectis' net margin of -114.82%. Amarin's return on equity of -17.21% beat Cellectis' return on equity.

Company Net Margins Return on Equity Return on Assets
Cellectis-114.82% -62.55% -21.19%
Amarin -41.07%-17.21%-12.16%

Cellectis has a beta of 2.91, meaning that its share price is 191% more volatile than the S&P 500. Comparatively, Amarin has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.

Summary

Cellectis beats Amarin on 11 of the 15 factors compared between the two stocks.

Get Cellectis News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLLS vs. The Competition

MetricCellectisMED IndustryMedical SectorNASDAQ Exchange
Market Cap$90.32M$2.93B$5.55B$9.01B
Dividend YieldN/A2.45%5.25%4.03%
P/E Ratio-1.8921.1428.0720.17
Price / Sales1.90288.66432.62124.64
Price / CashN/A41.1936.8257.86
Price / Book0.697.868.125.62
Net Income-$36.76M-$54.95M$3.16B$248.50M
7 Day Performance-1.52%6.24%4.40%5.54%
1 Month Performance14.04%5.70%4.10%7.52%
1 Year Performance-15.14%8.08%34.58%22.06%

Cellectis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLLS
Cellectis
3.0436 of 5 stars
$1.63
+0.9%
$4.00
+146.2%
-20.3%$90.32M$47.63M-1.89290Gap Down
AMRN
Amarin
0.6046 of 5 stars
$16.22
+3.2%
$12.00
-26.0%
+13.8%$335.92M$228.61M-4.46360High Trading Volume
AQST
Aquestive Therapeutics
1.3714 of 5 stars
$3.31
+1.8%
$10.14
+206.4%
+53.3%$328.78M$57.56M-5.61160
PRTA
Prothena
3.0359 of 5 stars
$6.07
-0.2%
$31.50
+418.9%
-67.7%$326.75M$135.16M-2.92130
TERN
Terns Pharmaceuticals
3.6987 of 5 stars
$3.73
-2.6%
$15.63
+318.9%
-39.8%$325.78MN/A-3.4240
PRME
Prime Medicine
4.0571 of 5 stars
$2.47
+2.1%
$10.08
+308.2%
-25.3%$324.30M$3.85M-1.20234Options Volume
High Trading Volume
HUMA
Humacyte
2.7384 of 5 stars
$2.09
-1.4%
$11.71
+460.5%
-54.7%$324.20M$1.57M-3.03150News Coverage
Analyst Forecast
SNDL
SNDL
3.5199 of 5 stars
$1.21
-1.6%
$3.63
+199.6%
-29.9%$317.96M$671.81M-4.172,516
HRTX
Heron Therapeutics
3.8416 of 5 stars
$2.07
-3.3%
$5.00
+141.5%
-25.9%$315.80M$144.29M-34.50300Positive News
AURA
Aura Biosciences
1.8869 of 5 stars
$6.26
-0.3%
$22.00
+251.4%
-14.6%$314.69MN/A-3.2950Positive News
ALT
Altimmune
2.2622 of 5 stars
$3.87
+10.6%
$19.00
+391.0%
-33.5%$313.90M$20K-3.0750High Trading Volume

Related Companies and Tools


This page (NASDAQ:CLLS) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners